Kefir for Critical Illness

Phase-Based Progress Estimates
Mayo Clinic Rochester, Rochester, MN
Critical Illness+1 More
Kefir - DietarySupplement
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to evaluate the safety and feasibility of kefir administration in critically ill adults.

Eligible Conditions

  • Critical Illness

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 30 days

30 days
Adverse Events
Feasibility of Kefir administration

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Kefir administration in critically ill adults
1 of 1
Experimental Treatment

45 Total Participants · 1 Treatment Group

Primary Treatment: Kefir · No Placebo Group · N/A

Kefir administration in critically ill adults
Experimental Group · 1 Intervention: Kefir · Intervention Types: DietarySupplement
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days
Closest Location: Mayo Clinic Rochester · Rochester, MN
Photo of Mayo Clinic Rochester 1Photo of Mayo Clinic Rochester 2Photo of Mayo Clinic Rochester 3
2005First Recorded Clinical Trial
1 TrialsResearching Critical Illness
157 CompletedClinical Trials

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,860 Previous Clinical Trials
3,686,116 Total Patients Enrolled
16 Trials studying Critical Illness
117,137 Patients Enrolled for Critical Illness
Lioudmila Karnatovskaia, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
62 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to tolerate oral diet or tube feeding.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.